B7-1 AMPLIFIES THE RESPONSE TO INTERLEUKIN-2-SECRETING TUMOR VACCINESIN-VIVO, BUT FAILS TO INDUCE A RESPONSE BY NAIVE CELLS IN-VITRO

Citation
S. Salvadori et al., B7-1 AMPLIFIES THE RESPONSE TO INTERLEUKIN-2-SECRETING TUMOR VACCINESIN-VIVO, BUT FAILS TO INDUCE A RESPONSE BY NAIVE CELLS IN-VITRO, Human gene therapy, 6(10), 1995, pp. 1299-1306
Citations number
28
Categorie Soggetti
Genetics & Heredity
Journal title
ISSN journal
10430342
Volume
6
Issue
10
Year of publication
1995
Pages
1299 - 1306
Database
ISI
SICI code
1043-0342(1995)6:10<1299:BATRTI>2.0.ZU;2-Z
Abstract
Parental and interleukin-2 (IL-2)-secreting CMS5 tumor cells were tran sfected with the B7-1 costimulatory molecule to amplify anti-tumor res ponses. CMS5 cells transfected with B7-1 grew more slowly in vivo than did parental CMS5 cells. Moreover, tumor cells secreting levels of IL -2 too low to cause rejection alone were rejected following transfecti on with B7-1. To determine whether the expression of B7-1 enabled the tumor cells to activate T cells directly, their ability to stimulate i n vitro functional responses by T cells was examined, We found that ne ither B7-1(+) nor IL-2-secreting, B7-1(+) CMS5 cells stimulated naive spleen cells to proliferate or to become cytotoxic. In contrast, resti mulation of primed T cells by B7-1(+) CMS5 cells resulted in stronger cytotoxicity responses than seen following restimulation by parental C MS5 cells, Lysis was even higher if the B7-1(+) tumor cells also secre ted IL-2. Our results suggest that the expression of costimulatory mol ecules can augment responses generated by vaccinating with IL-2-secret ing tumor cells, Furthermore, they are consistent with the hypothesis that the initiation of an anti-tumor response by naive T cells may dep end upon initial antigen presentation by another unidentified cell and that the major action of IL-2-secreting and/or B7-1(+) tumor cell vac cines might be to potentiate the response of already primed cells.